The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Bocchetta, Martina; Galluzzi, Samantha; Kehoe, Patrick; Aguera, Eduardo; Bernabei, Roberto; Bullock, Roger; Ceccaldi, Mathieu; Dartigues, Jean-Francois; de Mendonca, Alexandre; Didic, Mira; Eriksdotter, Maria; Felician, Olivier; Froelich, Lutz; Gertz, Hermann-Josef; Hallikainen, Merja; Hasselbalch, Steen; Hausner, Lucrezia; Heuser, Isabell; Jessen, Frank; Jones, Roy; Kurz, Alexander; Lawlor, Brian; Lleo, Alberto; Martinez-Lage, Pablo; Mecocci, Patrizia; Mehrabian, Shima; Monsch, Andreas; Nobili, Flavio; Nordberg, Agneta; Rikkert, Marcel; Orgogozo, Jean-Marc; Pasquier, Florence; Peters, Oliver; Salmon, Eric; Sanchez-Castellano, Carmen; Santana, Isabel; Sarazin, Marie; Traykov, Latchezar; Tsolaki, Magda; Visser, Pieter; Wallin, Asa; Wilcock, Gordon; Wilkinson, David; Wolf, Henrike; Yener, Goersev; Zekry, Dina; Frisoni, Giovanni

doi:10.1016/j.jalz.2014.06.006

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Atıf İçin Kopyala

Bocchetta M., Galluzzi S., Kehoe P. G., Aguera E., Bernabei R., Bullock R., ...Daha Fazla

ALZHEIMERS & DEMENTIA, cilt.11, sa.2, ss.195-206, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 11 Sayı: 2
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.jalz.2014.06.006
Dergi Adı: ALZHEIMERS & DEMENTIA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.195-206
Anahtar Kelimeler: Biomarkers, Alzheimer's disease, Mild cognitive impairment, Diagnosis, MILD COGNITIVE IMPAIRMENT, ALZHEIMERS ASSOCIATION WORKGROUPS, TEMPORAL-LOBE ATROPHY, CEREBROSPINAL-FLUID, NATIONAL INSTITUTE, VASCULAR DEMENTIA, VISUAL ASSESSMENT, CSF BIOMARKERS, F-18-FDG PET, DISEASE
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid position emission tomography [PET], cerebrospinal fluid [CSF] A beta 42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.